The Journal of community and supportive oncology最新文献_第8页

An ASCO 2017 recap: significant advances continue 2017年ASCO回顾:重大进展仍在继续

The Journal of community and supportive oncology Pub Date : 2017-08-01 DOI: 10.12788/jcso.0362

H. Burris

引用次数: 0

Bone remodeling associated with CTLA-4 inhibition: an unreported side effect 与CTLA-4抑制相关的骨重塑：一种未报道的副作用

The Journal of community and supportive oncology Pub Date : 2017-08-01 DOI: 10.12788/jcso.0340

Arpit Rao

引用次数: 1

Goals-of-care discussions. 照顾目标的讨论。

The Journal of community and supportive oncology Pub Date : 2017-07-01 DOI: 10.12788/jcso.0355

Catherine Saiki, Betty Ferrell, Denise Longo-Schoeberlein, Vincent Chung, Thomas J Smith

{"title":"Goals-of-care discussions.","authors":"Catherine Saiki, Betty Ferrell, Denise Longo-Schoeberlein, Vincent Chung, Thomas J Smith","doi":"10.12788/jcso.0355","DOIUrl":"https://doi.org/10.12788/jcso.0355","url":null,"abstract":"<p><p>Goals-of-care conversations led by the oncologist are key to advancing the prognostic awareness of the patient and family, but too frequently do not occur or are ineffective in leading to advance care planning and appropriate planning for end-of-life care. At our institution, a phase 3 trial of palliative care added to usual care of phase 1 clinical trial patients gave us the opportunity to develop an electronic medical record-based goals-of-care template for discussions. We can complete all or parts of the form with patients, use it to ensure full coverage of important tasks such as planning for transition to hospice and legacy work, and make sure all the providers are \"on the same page\" about treatment plans. We have this within our EMR as a SmartPhrase that can be brought up for completion, and have found that it helps to clarify patient understanding. The form can also be used to document advance care planning for both clinical care and billing. Although this tool has not been formally tested, we have found that it is effective in day-to-day practice as well as in research, and we share it here.</p>","PeriodicalId":75058,"journal":{"name":"The Journal of community and supportive oncology","volume":"15 4","pages":"e190-e194"},"PeriodicalIF":0.0,"publicationDate":"2017-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.12788/jcso.0355","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36431994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Approval makes olaratumab the first first-line treatment option for soft tissue sarcoma in more than 40 years 批准使olaratumab成为40多年来第一个软组织肉瘤的一线治疗选择

The Journal of community and supportive oncology Pub Date : 2017-07-01 DOI: 10.12788/JCSO.0360

J. D. Lartigue

引用次数: 0

Prehabilitation for lymphedema in head and neck cancer patients at a community cancer center 社区癌症中心头颈癌患者淋巴水肿的预康复

The Journal of community and supportive oncology Pub Date : 2017-05-01 DOI: 10.12788/JCSO.0345

A. Sember, C. Pranskevich, S. Scott, I. Hutchinson, R. Hoffman

引用次数: 6

A rare case of hypoglycemia induced by a classic gastrointestinal stromal tumor 一例罕见的由典型胃肠道间质瘤引起的低血糖

The Journal of community and supportive oncology Pub Date : 2017-05-01 DOI: 10.12788/jcso.0275

Sorab Gupta, V. Mehta, Shradha Ahuja, M. Punj, Oscar Carazas, Massoud G Kazzi

引用次数: 0

Pancreatitis associated with newer classes of antineoplastic therapies 与新型抗肿瘤治疗相关的胰腺炎

The Journal of community and supportive oncology Pub Date : 2017-05-01 DOI: 10.12788/JCSO.0347

G. Clamon, Ravi C. Patel, S. Mott

{"title":"Pancreatitis associated with newer classes of antineoplastic therapies","authors":"G. Clamon, Ravi C. Patel, S. Mott","doi":"10.12788/JCSO.0347","DOIUrl":"https://doi.org/10.12788/JCSO.0347","url":null,"abstract":"Patients with advanced malignancies may develop pancreatitis during therapy for their cancer. Acute pancreatitis is inflammation of the pancreas. Common symptoms include abdominal pain, nausea, vomiting, shortness of breath, dehydration. Laboratory evidence of acute pancreatitis includes elevations of the amylase and lipase. Mild pancreatitis occurs when there is no organ dysfunction, moderate pancreatitis is associated with one organ dysfunction, and severe pancreatitis is complicated by multiple organ dysfunction. Hypotension, hypocalcemia, or anemia suggest a more severe course of the pancreatitis. In some instances, the pancreatitis may be an adverse reaction to the therapy being given. However, other causes such as hypercalcemia, hypertriglyceridemia, cholelithiasis, and underlying malignancy must be ruled out before ascribing pancreatitis to a specific drug. To date, two classifications systems have been proposed by Trivedi1 and Badalov2 to evaluate the degree to which a drug is responsible for pancreatitis (Table 1). Furthermore, Naranjo and colleagues have proposed a more general method of assessing the causal relationship between drugs and adverse events.3 The Naranjo algorithm is not specific for pancreatitis. Jones and colleagues4 reported that 0.1%-2% of acute pancreatitis cases were owing to drugs. In 2015, they listed the older chemotherapy agents associated with pancreatitis. However, more recently, many new agents have been approved for the management of cancers. The newer classes of antineoplastic agents including proteasome inhibitors, immune-modulating agents, tyrosine kinase inhibitors, monoclonal antibodies against programmed cell death-1 (PD-1) and its ligand PD-L1 and antibody-toxin conjugates are now associated with acute pancreatitis.","PeriodicalId":75058,"journal":{"name":"The Journal of community and supportive oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49577350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Physician attitudes and prevalence of molecular testing in lung cancer 肺癌分子检测的医师态度和流行程度

The Journal of community and supportive oncology Pub Date : 2017-05-01 DOI: 10.12788/JCSO.0326

R. Rao, Z. Otaibi, Matthew Bartock, Mamatha Gaddam, A. Zaidi, B. Jobe, G. Finley

{"title":"Physician attitudes and prevalence of molecular testing in lung cancer","authors":"R. Rao, Z. Otaibi, Matthew Bartock, Mamatha Gaddam, A. Zaidi, B. Jobe, G. Finley","doi":"10.12788/JCSO.0326","DOIUrl":"https://doi.org/10.12788/JCSO.0326","url":null,"abstract":"Lung cancer is the leading cause of cancer death in the United States. It is estimated that there will be 222,500 new cases of lung cancer and 155,870 deaths from lung cancer in 2017. Non–small-cell lung carcinoma (NSCLC) accounts for 80%-85% of lung cancers, with adenocarcinoma being the most common histologic subtype. Other less common subtypes include squamous-cell carcinoma, large-cell carcinoma, and NSCLC that cannot be further classified.1 Nearly 70% of patients present with locally advanced or metastatic disease at the time of diagnosis and are not candidates for surgical resection.2 For that group of patients, the mainstay of treatment is platinumbased chemotherapy with or without radiation therapy. Patients who are chemotherapy naive often experience a modest response, however; durable remission is short lived, and the 5-year survival rate remains staggeringly low.3 Improved understanding of the molecular pathways that drive malignancy in NSCLC has led to the development of drugs that target specific molecular pathways.4 By definition, these driver mutations facilitate oncogenesis by conferring a selective advantage during clonal evolution.5 Moreover, agents targeting these pathways are extremely active and induce durable responses in many patients.6,7,8 Predictive biomarkers in NSCLC include anaplastic lymphoma kinase (ALK) fusion oncogene and sensitizing epidermal growth factor receptor (EGFR) mutations. Mutations in the EGFR tyrosine kinase are observed in about 15%-20% of NSCLC adenocarcinomas in the United States and upward of 60% in Asian populations. They are also found more frequently in nonsmokers and women.6 The two most prevalent mutations in the EGFR tyrosine kinase domain are in-frame deletions of exon 19 and L858R substitution in exon 21, representing about 45% and 40% of mutations, respectively.9 Both mutations result in activation of the tyrosine kinase domain, and both are associated with sensitivity to the small-molecule tyrosine","PeriodicalId":75058,"journal":{"name":"The Journal of community and supportive oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48349347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Perceived financial hardship among patients with advanced cancer 晚期癌症患者感受到的经济困难

The Journal of community and supportive oncology Pub Date : 2017-05-01 DOI: 10.12788/JCSO.0341

S. Gallups, V. Copeland, M. Rosenzweig

{"title":"Perceived financial hardship among patients with advanced cancer","authors":"S. Gallups, V. Copeland, M. Rosenzweig","doi":"10.12788/JCSO.0341","DOIUrl":"https://doi.org/10.12788/JCSO.0341","url":null,"abstract":"The American Cancer Society has identified a disparity in cancer death rates, noting that persons with lower socioeconomic status have higher rates of mortality.1 This is attributed to many factors, but it is largely owing to the higher burden of disease among lower-income individuals.1 A component of this disease burden is measured by assessing the patient-reported outcome of cancer-related distress. The National Comprehensive Cancer Network (NCCN) Distress Management Guidelines have defined distress as “a multifactorial unpleasant emotional experience of a psychological (cognitive, behavioral, emotional), social and/or spiritual nature that may interfere with the ability to cope with cancer, its physical symptoms and its treatment.”2 Financial hardship related to cancer diagnosis and treatment is increasingly being recognized as an important component of disease burden and distress. The advancements in costly cancer treatments have produced burdensome direct medical costs as well as numerous indirect costs that contribute to perceived financial hardship.3,4 These indirect costs include nonmedical expenses such as increased transportation needs or childcare, loss of earnings, or loss of household income due to caregiving needs.3 Moreover, indirect costs are often managed by patients and families through their use of savings, borrowing, reducing leisure activities, and selling possessions.3 Even though efforts to increase health coverage, such as the Affordable Care Act, have reduced the rates of individuals who are uninsured, persons with cancer who have insurance also face challenges because they cannot afford copays, monthly premiums, deductibles, and other high out-of-pocket expenses related to cancer treatment that are not covered by their insurance such as out-of-network services or providers.5-7 Thus, financial hardship may have an impact","PeriodicalId":75058,"journal":{"name":"The Journal of community and supportive oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45539040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Bilateral chylothorax in an AIDS patient with newly diagnosed Kaposi sarcoma 双侧乳糜胸伴新诊断的卡波西肉瘤1例

The Journal of community and supportive oncology Pub Date : 2017-05-01 DOI: 10.12788/JCSO.0261

Rebecca Neril, K. Lam

引用次数: 1